Polymeric nanoencapsulation of zaleplon into PLGA nanoparticles for enhanced pharmacokinetics and pharmacological activity

Yusuf A. Haggag, Ahmed Kh Abosalha, Murtaza M. Tambuwala, Enass Y. Osman, Sanaa A. El-Gizawy, Ebtessam A. Essa, Ahmed A. Donia

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)
141 Downloads (Pure)


Zaleplon (ZP) is a sedative and hypnotic drug used for the treatment of insomnia. Despite its potent anticonvulsant activity, ZP is not commonly used for the treatment of convulsion since ZP is characterized by its low oral bioavailability as a result of poor solubility and extensive liver metabolism. The following study aimed to formulate specifically controlled release nano-vehicles for oral and parenteral delivery of ZP to enhance its oral bioavailability and biological activity. A modified single emulsification–solvent evaporation method of sonication force was adopted to optimize the inclusion of ZP into biodegradable nanoparticles (NPs) using poly (dl-lactic-co-glycolic acid) (PLGA). The impacts of various formulation variables on the physicochemical characteristics of the ZP-PLGA-NPs and drug release profiles were investigated. Pharmacokinetics and pharmacological activity of ZP-PLGA-NPs were studied using experimental animals and were compared with generic ZP tablets. Assessment of gamma-aminobutyric acid (GABA) level in plasma after oral administration was conducted using enzyme-linked immunosorbent assay. The maximal electroshock-induced seizures model evaluated anticonvulsant activity after the parenteral administration of ZP-loaded NPs. The prepared ZP-PLGA NPs were negatively charged spherical particles with an average size of 120–300 nm. Optimized ZP-PLGA NPs showed higher plasma GABA levels, longer sedative, hypnotic effects, and a 3.42-fold augmentation in oral drug bioavailability in comparison to ZP-marketed products. Moreover, parenteral administration of ZP-NPs showed higher anticonvulsant activity compared to free drug. Oral administration of ZP-PLGA NPs achieved a significant improvement in the drug bioavailability, and parenteral administration showed a pronounced anticonvulsant activity.

Original languageEnglish
Pages (from-to)12-23
Number of pages12
JournalBiopharmaceutics and Drug Disposition
Issue number1
Early online date15 Dec 2020
Publication statusPublished (in print/issue) - 31 Jan 2021

Bibliographical note

Funding Information:
The authors wish to thank Tanta University for their financial support for this project.

Publisher Copyright:
© 2021 The Authors. Biopharmaceutics & Drug Disposition published by John Wiley & Sons Ltd.

Copyright 2021 Elsevier B.V., All rights reserved.


  • anticonvulsant activity
  • formulation variables
  • GABA
  • nanoparticles
  • optimization
  • oral bioavailability
  • pharmacokinetics
  • PLGA
  • zaleplon
  • Pharmaceutical Science
  • General Medicine
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Polymeric nanoencapsulation of zaleplon into PLGA nanoparticles for enhanced pharmacokinetics and pharmacological activity'. Together they form a unique fingerprint.

Cite this